Publications by authors named "C Czudek"
Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a 1+1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs, 15-valent PCV (PCV15), or 20-valent PCV (PCV20) might be considered to expand serotype coverage. We evaluated the cost-effectiveness of PCV20 or PCV15 using either a 2+1 (2 primary doses) or 1+1 schedule for pediatric immunization in the UK.
View Article and Find Full Text PDFInfectious diseases are a leading cause of morbidity and mortality worldwide with vaccines playing a critical role in preventing deaths. To better understand the impact of low vaccination rates and previous epidemics on infectious disease rates, and how these may help to understand the potential impacts of the current coronavirus disease 2019 (COVID-19) pandemic, a targeted literature review was conducted. Globally, studies suggest past suboptimal vaccine coverage has contributed to infectious disease outbreaks in vulnerable populations.
View Article and Find Full Text PDFArticle Synopsis
- The UK will soon stop using a combined Hib/MenC vaccine due to discontinuation by the manufacturer, prompting the JCVI to recommend halting MenC immunization at 12 months.
- A study modeled various meningococcal vaccination strategies, finding that giving MenACWY shots at 2, 4, and 12 months, alongside the adolescent program, could prevent 269 IMD cases and 13 deaths.
- The findings suggest that without the MenC toddler vaccine, there’s a risk of increased IMD cases, highlighting the need for effective infant and toddler MenACWY immunization strategies to maintain public health.
Background: We aimed to estimate the public health impact of booster vaccination against COVID-19 in the UK during an Omicron-predominant period.
Research Design And Methods: A dynamic transmission model was developed to compare public health outcomes for actual and alternative UK booster vaccination programs. Input sources were publicly available data and targeted literature reviews.
Aim: To evaluate the public health impact of the UK COVID-19 booster vaccination program in autumn 2021, during a period of SARS-CoV-2 Delta variant predominance.
Materials And Methods: A compartmental Susceptible-Exposed-Infectious-Recovered model was used to compare age-stratified health outcomes for adult booster vaccination versus no booster vaccination in the UK over a time horizon of September-December 2021, when boosters were introduced in the UK and the SARS-CoV-2 Delta variant was predominant. Model input data were sourced from targeted literature reviews and publicly available data.